Please join us for this scientific webinar to get insight on how you can take your in-house protein quantification to the next level with the new Olink Signature Q100 together with Olink’s Target Platform on
27th of September 2022 at 11:00 CET.
This webinar will include a technical introduction to Olink Signature Q100 and Olink Target Platforms. It will cover topics such as product portfolio, panel design, workflow overview, correlation to established clinical assays and application examples. We will also walk through the process for taking the technology in-house including the Olink Training Process.
Olink’s Target 48/96 product range is built on Olink’s PEA technology that offers high-multiplex quantification of protein biomarkers with high sensitivity and a broad dynamic range.
Anna Lejon
Business Development Manager, Nordics
Olink Proteomics
Sandra Kyrk
Business Development Manager, Stockholm and Norway
Olink Proteomics
Olga Surova, PhD
Field Application Scientist Nordics
Olink Proteomics
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.